CMF (chemotherapy)
Template:Short description Template:Short description Script error: No such module "Infobox".Template:Template otherScript error: No such module "Check for unknown parameters". Cyclophosphamide Methotrexate Fluorouracil (CMF) is a commonly used regimen of breast cancer chemotherapy that combines three anti-cancer agents: cyclophosphamide, methotrexate, and 5-fluorouracil (5-FU).[1]
While it is no longer considered the most efficient all-around chemotherapy, it retains a great importance in the treatment of elderly patients with luminal cancers and may become important for the treatment of estrogen receptor negative androgen receptor positive luminal (GATA3 expressing) breast cancer.
The regimen was designed in order to mimic the highly successful regimen developed to treat Hodgkin's lymphoma.[2]
Treatment
The treatment is administered over a four-week cycle. On days 1 and 8 methotrexate and 5-FU are given as injections. Cyclophosphamide may be also administered intravenously in conjunction with these drugs, or may be taken as an oral tablet, taken once each day for the first 14 days of each cycle.[3]
Side effects
Side effects of CMF treatment include:[3]
<templatestyles src="Div col/styles.css"/>
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".